Thus, as ketogenesis prevents diet-induced fatty liver injury and hyperglycaemia37, CREB3L3 may represent a new therapeutic target for NAFLD. This evidence concerns the gene CREB3L3 and metabolic dysfunction-associated steatotic liver disease.